Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01281.x/abstract

Clevudine for chronic hepatitis B: antiviral response, predictors of response,

and development of myopathy

J.-H. Jang†, J.-W. Kim†, S.-H. Jeong, H.-J. Myung, H. S. Kim, Y. S. Park, S.

H. Lee, J.-H. Hwang, N. Kim, D. H. LeeArticle first published

online: 26 FEB 2010

DOI: 10.1111/j.1365-2893.2010.01281.x

© 2010 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Volume 18, Issue 2, pages 84–90, February 2011

Summary.  Clevudine has been approved for the treatment of chronic hepatitis B

(CHB) in South Korea. However, its long-term antiviral effect and safety awaits

more study. The aim of this study was to evaluate antiviral efficacy, predictors

of virologic response, and development of myopathy after clevudine therapy for

CHB. The study included 102 nucleoside naïve CHB patients who had received

clevudine for more than 6 months with good compliance. The median duration of

clevudine treatment was 53 weeks (range, 25–90 weeks). A retrospective

analysis of data retrieved from medical records was performed. The cumulative

rate of virologic response [hepatitis B virus (HBV) DNA level <2000 copies/mL]

at 48 weeks of clevudine therapy was 81%, and cumulative rate of clevudine

resistance was 11% at 60 weeks of treatment. Independent predictors of virologic

response to clevudine therapy were hepatitis B e antigen (HBeAg) negativity and

rapid decrease of viral load during the early phase of treatment. The

clevudine-related myopathy developed in 3.9% of patients, and was reversible

after discontinuation of clevudine. Clevudine showed a potent antiviral

response, and its effect was higher in HBeAg-negative patients, with rapid viral

load reduction after therapy. However, long-term therapy for more than 1 year

resulted in the development of considerable resistance and myopathy. Therefore,

we should consider alternative antiviral agents if clevudine resistance or

clevudine-induced myopathy is developed in patients on clevudine for the

treatment of CHB.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01281.x/abstract

Clevudine for chronic hepatitis B: antiviral response, predictors of response,

and development of myopathy

J.-H. Jang†, J.-W. Kim†, S.-H. Jeong, H.-J. Myung, H. S. Kim, Y. S. Park, S.

H. Lee, J.-H. Hwang, N. Kim, D. H. LeeArticle first published

online: 26 FEB 2010

DOI: 10.1111/j.1365-2893.2010.01281.x

© 2010 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Volume 18, Issue 2, pages 84–90, February 2011

Summary.  Clevudine has been approved for the treatment of chronic hepatitis B

(CHB) in South Korea. However, its long-term antiviral effect and safety awaits

more study. The aim of this study was to evaluate antiviral efficacy, predictors

of virologic response, and development of myopathy after clevudine therapy for

CHB. The study included 102 nucleoside naïve CHB patients who had received

clevudine for more than 6 months with good compliance. The median duration of

clevudine treatment was 53 weeks (range, 25–90 weeks). A retrospective

analysis of data retrieved from medical records was performed. The cumulative

rate of virologic response [hepatitis B virus (HBV) DNA level <2000 copies/mL]

at 48 weeks of clevudine therapy was 81%, and cumulative rate of clevudine

resistance was 11% at 60 weeks of treatment. Independent predictors of virologic

response to clevudine therapy were hepatitis B e antigen (HBeAg) negativity and

rapid decrease of viral load during the early phase of treatment. The

clevudine-related myopathy developed in 3.9% of patients, and was reversible

after discontinuation of clevudine. Clevudine showed a potent antiviral

response, and its effect was higher in HBeAg-negative patients, with rapid viral

load reduction after therapy. However, long-term therapy for more than 1 year

resulted in the development of considerable resistance and myopathy. Therefore,

we should consider alternative antiviral agents if clevudine resistance or

clevudine-induced myopathy is developed in patients on clevudine for the

treatment of CHB.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01281.x/abstract

Clevudine for chronic hepatitis B: antiviral response, predictors of response,

and development of myopathy

J.-H. Jang†, J.-W. Kim†, S.-H. Jeong, H.-J. Myung, H. S. Kim, Y. S. Park, S.

H. Lee, J.-H. Hwang, N. Kim, D. H. LeeArticle first published

online: 26 FEB 2010

DOI: 10.1111/j.1365-2893.2010.01281.x

© 2010 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Volume 18, Issue 2, pages 84–90, February 2011

Summary.  Clevudine has been approved for the treatment of chronic hepatitis B

(CHB) in South Korea. However, its long-term antiviral effect and safety awaits

more study. The aim of this study was to evaluate antiviral efficacy, predictors

of virologic response, and development of myopathy after clevudine therapy for

CHB. The study included 102 nucleoside naïve CHB patients who had received

clevudine for more than 6 months with good compliance. The median duration of

clevudine treatment was 53 weeks (range, 25–90 weeks). A retrospective

analysis of data retrieved from medical records was performed. The cumulative

rate of virologic response [hepatitis B virus (HBV) DNA level <2000 copies/mL]

at 48 weeks of clevudine therapy was 81%, and cumulative rate of clevudine

resistance was 11% at 60 weeks of treatment. Independent predictors of virologic

response to clevudine therapy were hepatitis B e antigen (HBeAg) negativity and

rapid decrease of viral load during the early phase of treatment. The

clevudine-related myopathy developed in 3.9% of patients, and was reversible

after discontinuation of clevudine. Clevudine showed a potent antiviral

response, and its effect was higher in HBeAg-negative patients, with rapid viral

load reduction after therapy. However, long-term therapy for more than 1 year

resulted in the development of considerable resistance and myopathy. Therefore,

we should consider alternative antiviral agents if clevudine resistance or

clevudine-induced myopathy is developed in patients on clevudine for the

treatment of CHB.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01281.x/abstract

Clevudine for chronic hepatitis B: antiviral response, predictors of response,

and development of myopathy

J.-H. Jang†, J.-W. Kim†, S.-H. Jeong, H.-J. Myung, H. S. Kim, Y. S. Park, S.

H. Lee, J.-H. Hwang, N. Kim, D. H. LeeArticle first published

online: 26 FEB 2010

DOI: 10.1111/j.1365-2893.2010.01281.x

© 2010 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Volume 18, Issue 2, pages 84–90, February 2011

Summary.  Clevudine has been approved for the treatment of chronic hepatitis B

(CHB) in South Korea. However, its long-term antiviral effect and safety awaits

more study. The aim of this study was to evaluate antiviral efficacy, predictors

of virologic response, and development of myopathy after clevudine therapy for

CHB. The study included 102 nucleoside naïve CHB patients who had received

clevudine for more than 6 months with good compliance. The median duration of

clevudine treatment was 53 weeks (range, 25–90 weeks). A retrospective

analysis of data retrieved from medical records was performed. The cumulative

rate of virologic response [hepatitis B virus (HBV) DNA level <2000 copies/mL]

at 48 weeks of clevudine therapy was 81%, and cumulative rate of clevudine

resistance was 11% at 60 weeks of treatment. Independent predictors of virologic

response to clevudine therapy were hepatitis B e antigen (HBeAg) negativity and

rapid decrease of viral load during the early phase of treatment. The

clevudine-related myopathy developed in 3.9% of patients, and was reversible

after discontinuation of clevudine. Clevudine showed a potent antiviral

response, and its effect was higher in HBeAg-negative patients, with rapid viral

load reduction after therapy. However, long-term therapy for more than 1 year

resulted in the development of considerable resistance and myopathy. Therefore,

we should consider alternative antiviral agents if clevudine resistance or

clevudine-induced myopathy is developed in patients on clevudine for the

treatment of CHB.